| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/15-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | p28; IL30; IL-27; IL27A; IL-27A; IL27p28 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human IL27 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于IL27抗体的代表性文献摘要(文献信息为模拟示例，仅供参考)：
1. **文献名称**：*Anti-IL-27 Antibody Attenuates Experimental Autoimmune Encephalomyelitis via Suppressing Th17 Cell Development*
**作者**：Smith A, et al.
**摘要**：该研究通过动物实验证明，IL27中和抗体能抑制Th17细胞分化，减轻多发性硬化模型小鼠的神经炎症和病理损伤，提示靶向IL27可能用于自身免疫疾病治疗。
2. **文献名称**：*Blockade of IL-27 Signaling Enhances Antitumor Immunity in Colorectal Cancer*
**作者**：Chen L, et al.
**摘要**：研究发现IL27抗体通过阻断IL27/WSX-1信号通路，增强CD8+ T细胞的抗肿瘤活性，并与化疗药物协同抑制结直肠癌小鼠模型中的肿瘤生长。
3. **文献名称**：*IL-27 Neutralization Reduces Psoriasis-like Skin Inflammation via Modulating Dendritic Cell Function*
**作者**：Wang Y, et al.
**摘要**：该文献揭示IL27抗体可通过调控树突状细胞的促炎因子分泌，改善银屑病样皮肤炎症，为IL27在慢性炎症中的靶向干预提供依据。
注：以上内容为模拟生成，实际文献需通过PubMed/Google Scholar等平台检索确认。
IL-27 is a heterodimeric cytokine composed of p28 and Epstein-Barr virus-induced gene 3 (EBI3) subunits, primarily secreted by antigen-presenting cells such as dendritic cells and macrophages. It signals through a receptor complex comprising IL-27Rα (WSX-1) and gp130. activating downstream pathways like JAK-STAT, which regulate immune responses. IL-27 plays dual roles in immunity, balancing pro-inflammatory and anti-inflammatory effects. It promotes Th1 differentiation and antiviral responses while suppressing Th17 and Th2 cells, making it critical in autoimmune diseases, infections, and cancer. Dysregulated IL-27 signaling is linked to conditions like multiple sclerosis, inflammatory bowel disease, and certain cancers.
IL-27 antibodies are tools to modulate or detect IL-27 activity. Neutralizing antibodies block IL-27/receptor interactions, potentially curbing its pro-inflammatory effects in autoimmune disorders or enhancing antitumor immunity in cancer. Conversely, agonist antibodies might exploit IL-27’s anti-inflammatory properties to treat chronic inflammation. Diagnostic antibodies aid in quantifying IL-27 levels in research or clinical settings. Preclinical studies using IL-27 antibodies in models like experimental autoimmune encephalomyelitis (EAE) or colitis show therapeutic promise, though clinical translation remains limited. Challenges include IL-27’s context-dependent functions, necessitating precise targeting strategies. Research continues to clarify its mechanistic nuances and optimize antibody-based interventions.
×
